Justin C Moser, Mateusz Opyrchal, Ildefonso Rodriguez Rivera, Mehmet A Bilen, Brendan Curti, Igor Puzanov, Kristin Morris, Christopher J Nirschl, Saero Park, Marissa Bruno, Paul Windt, Kulandayan K Subramanian, Sameer S Chopra, Randi Isaacs
{"title":"737a肿瘤激活的IL-2前药WTX-124单独或联合pembrolizumab用于免疫治疗敏感的局部晚期或转移性实体瘤患者的1/1b期研究","authors":"Justin C Moser, Mateusz Opyrchal, Ildefonso Rodriguez Rivera, Mehmet A Bilen, Brendan Curti, Igor Puzanov, Kristin Morris, Christopher J Nirschl, Saero Park, Marissa Bruno, Paul Windt, Kulandayan K Subramanian, Sameer S Chopra, Randi Isaacs","doi":"10.1136/jitc-2023-sitc2023.0737","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":500964,"journal":{"name":"Regular and Young Investigator Award Abstracts","volume":"19 3","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"737 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastatic solid tumors\",\"authors\":\"Justin C Moser, Mateusz Opyrchal, Ildefonso Rodriguez Rivera, Mehmet A Bilen, Brendan Curti, Igor Puzanov, Kristin Morris, Christopher J Nirschl, Saero Park, Marissa Bruno, Paul Windt, Kulandayan K Subramanian, Sameer S Chopra, Randi Isaacs\",\"doi\":\"10.1136/jitc-2023-sitc2023.0737\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":500964,\"journal\":{\"name\":\"Regular and Young Investigator Award Abstracts\",\"volume\":\"19 3\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Regular and Young Investigator Award Abstracts\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/jitc-2023-sitc2023.0737\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Regular and Young Investigator Award Abstracts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/jitc-2023-sitc2023.0737","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
737 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastatic solid tumors